Shanghai Fu Honghanlin is a biopharmaceutical company dedicated to the development of monoclonal antibody drugs and the research in the field of tumor treatment. The company has a relatively strong background, certain R&D capabilities and technical advantages, and some successful products have been listed.
The company's development prospects are also relatively good, with certain achievements in domestic and foreign markets and certain competitiveness. The company also pays attention to the career development and training of employees, providing a good career development platform and promotion opportunities.